Novo Not Discussing Further Pill Discounts, CEO Says
Share
Novo Nordisk A/S Chief Executive Officer Mike Doustdar talks about the company's performance as its popular Wegovy weight-loss pill disappointed investors with sales that failed to live up to the hype. "We are not right now discussing further discounts," Doustdar tells Bloomberg's Francine Lacqua.